Experienced in Empyema

Dr. Matthew G. Davis

Family Medicine
Centers For Family Medicine Gp
10601 Walker St, Suite 250, 
Cypress, CA 
Clinical Trials:Currently Recruiting for 3 Trials
Offers Telehealth
Experienced in Empyema
Centers For Family Medicine Gp
10601 Walker St, Suite 250, 
Cypress, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Matthew Davis is a primary care provider, practicing in Family Medicine in Cypress, California. Dr. Davis is rated as an Experienced provider by MediFind in the treatment of Empyema. His top areas of expertise are Hypertension, Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, and Migraine.

His clinical research consists of co-authoring 15 peer reviewed articles and participating in 35 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Family Medicine
Licenses
Family Medicine in CA
Hospital Affiliations
Memorialcare Long Beach Medical Center
Uci Health - Los Alamitos
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
HMSA
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

CENTERS FOR FAMILY MEDICINE GP
10601 Walker St, Suite 250, Cypress, CA 90630

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

28 Clinical Trials

A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine
A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Biological, Drug
Study Drugs: RSVPreF3, Boostrix-ex-US, Boostrix-US
Study Phase: Phase 2
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Safety and Immunogenicity of GSK's Rabies G SAM (CNE) Vaccine [GSK3903133A] in Healthy Adults.
Safety and Immunogenicity of GSK's Rabies G SAM (CNE) Vaccine [GSK3903133A] in Healthy Adults.
Enrollment Status: Completed
Publish Date: March 01, 2024
Intervention Type: Biological, Drug
Study Drugs: Rabies Glycoprotein G Vaccine, RabAvert Rabies Vaccine
Study Phase: Phase 1
A Phase I, First-Time-in Human (FTiH), Open-label, Dose Escalation, Non-randomized Study to Assess Safety, Reactogenicity and Immune Response of a CoV-2 SAM (LNP) Vaccine When Administered Intramuscularly on a 0, 1 Month Schedule in Healthy Adults 18 to 50 Years of Age
A Phase I, First-Time-in Human (FTiH), Open-label, Dose Escalation, Non-randomized Study to Assess Safety, Reactogenicity and Immune Response of a CoV-2 SAM (LNP) Vaccine When Administered Intramuscularly on a 0, 1 Month Schedule in Healthy Adults 18 to 50 Years of Age
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Biological
Study Drug: CoV-2 Self-Amplifying mRNA Lipid Nanoparticle Vaccine
Study Phase: Phase 1
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
Enrollment Status: Active_not_recruiting
Publish Date: December 21, 2023
Intervention Type: Biological
Study Drug: RSVPreF3 OA investigational vaccine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (Cholera Vaccine, Live, Oral) in Children 2 to <18 Years of Age
A Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (Cholera Vaccine, Live, Oral) in Children 2 to <18 Years of Age
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Biological, Other
Study Phase: Phase 4
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
A Phase 2b, Open-label, Multi-center, Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 Older Adults (OA) Investigational Vaccine Administered Intramuscularly 18 Months Post-Dose 2 in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study
A Phase 2b, Open-label, Multi-center, Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 Older Adults (OA) Investigational Vaccine Administered Intramuscularly 18 Months Post-Dose 2 in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study
Enrollment Status: Completed
Publish Date: June 29, 2022
Intervention Type: Biological
Study Drug: RSVPreF3 OA investigational vaccine
Study Phase: Phase 2
A Phase 4 Single-Blind Study of Gastrointestinal Transit Time in Adult Patients With Migraine Before and After Initiation of a mAb CGRP Antagonist
A Phase 4 Single-Blind Study of Gastrointestinal Transit Time in Adult Patients With Migraine Before and After Initiation of a mAb CGRP Antagonist
Enrollment Status: Completed
Publish Date: March 22, 2022
Intervention Type: Drug
Study Phase: Phase 4
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Unadjuvanted RSV Maternal Vaccine Compared to Placebo When Administered to Healthy Non-pregnant Women.
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Unadjuvanted RSV Maternal Vaccine Compared to Placebo When Administered to Healthy Non-pregnant Women.
Enrollment Status: Completed
Publish Date: August 13, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Phase I, Single-blind, Randomised, Placebo-controlled, Dose Escalation Study to Evaluate the Reactogenicity, Safety and Immune Response of an HSV Vaccine in Healthy Participants Aged 18-40 Years
A Phase I, Single-blind, Randomised, Placebo-controlled, Dose Escalation Study to Evaluate the Reactogenicity, Safety and Immune Response of an HSV Vaccine in Healthy Participants Aged 18-40 Years
Enrollment Status: Terminated
Publish Date: June 28, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: August 19, 2020
Intervention Type: Drug
Study Phase: Phase 3
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Homologous and Heterologous Prime-Boost Vaccination Strategies With Stockpiled Inactivated Monovalent Influenza A(H5) Vaccines Administered Intramuscularly With Either AS03 or MF59® as Adjuvant
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Homologous and Heterologous Prime-Boost Vaccination Strategies With Stockpiled Inactivated Monovalent Influenza A(H5) Vaccines Administered Intramuscularly With Either AS03 or MF59® as Adjuvant
Enrollment Status: Completed
Publish Date: July 14, 2020
Intervention Type: Biological
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Enrollment Status: Completed
Publish Date: July 08, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy
A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy
Enrollment Status: Completed
Publish Date: June 25, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
LY2951742 Biomarker Study in Patients With Migraine
LY2951742 Biomarker Study in Patients With Migraine
Enrollment Status: Completed
Publish Date: April 09, 2019
Intervention Type: Drug
Study Phase: Early Phase 1
Open-Label, Multicenter Study Evaluating the Safety and Efficacy of the Nicotine Replacement Therapy Chrono Quit Smoking Solution (CQSS2) System (21mg) Compared to the NicoDerm® CQ® Patch (21mg) for Smoking Cessation in Treatment Seeking Subjects
Open-Label, Multicenter Study Evaluating the Safety and Efficacy of the Nicotine Replacement Therapy Chrono Quit Smoking Solution (CQSS2) System (21mg) Compared to the NicoDerm® CQ® Patch (21mg) for Smoking Cessation in Treatment Seeking Subjects
Enrollment Status: Completed
Publish Date: December 04, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 25 Less Clinical Trials

15 Total Publications

Secondary Pneumococcal Disease in Veterans with Viral Respiratory Infections.
Secondary Pneumococcal Disease in Veterans with Viral Respiratory Infections.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: March 20, 2025
Similar Doctors
Distinguished in Empyema
Dr. Nahla H. Salem
Family Medicine
Distinguished in Empyema
Dr. Nahla H. Salem
Family Medicine
8101 Newman Avenue, Suite B, 
Huntington Beach, CA 
 (6.2 miles away)
714-847-3030
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nahla Salem is a primary care provider, practicing in Family Medicine in Huntington Beach, California. Dr. Salem is rated as a Distinguished provider by MediFind in the treatment of Empyema. Her top areas of expertise are Acute Cystitis, Otitis, Cellulitis, and Urinary Tract Infection in Children. Dr. Salem is currently accepting new patients.

Advanced in Empyema
Dr. Steven S. Ghalili
Family Medicine
Advanced in Empyema
Dr. Steven S. Ghalili
Family Medicine
648 E 21st St, 
Los Angeles, CA 
 (19.6 miles away)
310-488-1391
Languages Spoken:
English
See accepted insurances

Steven Ghalili is a primary care provider, practicing in Family Medicine in Los Angeles, California. Dr. Ghalili is rated as an Advanced provider by MediFind in the treatment of Empyema. His top areas of expertise are Pharyngomaxillary Space Abscess, Sinusitis, Empyema, and Sitosterolemia.

Advanced in Empyema
Dr. Ketsana Vilaysane
Family Medicine
Advanced in Empyema
Dr. Ketsana Vilaysane
Family Medicine

Providence Medical Foundation

1950 Sunny Crest Dr, Suite 2900, 
Fullerton, CA 
 (8.4 miles away)
714-992-5350
Languages Spoken:
English
See accepted insurances

Ketsana Vilaysane is a primary care provider, practicing in Family Medicine in Fullerton, California. Dr. Vilaysane is rated as an Advanced provider by MediFind in the treatment of Empyema. His top areas of expertise are Cellulitis, Sinusitis, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), and Peptic Ulcer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Davis's expertise for a condition
ConditionClose
      View All 116 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile